Codexis, Inc.

CDXS Healthcare Biotechnology

Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.

1.25 0.11 −8.09%
Market cap
$148.9M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−4.75
Beneish M
−3.57
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
3 2 4 2 3 3 4 3 3 4
P/S ratio
3.74 7.53 14.39 13.20 18.76 19.27 2.20 3.03 5.90 2.02
Altman Z-Score
(3.62) (0.29) 17.98 10.21 13.59 13.32 0.01 (3.23) (3.02) (4.75)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 101.52 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(24.38) (18.69) (7.83) (1.16) 2.07 (0.22) (2.00) (10.64) (10.79) (11.56)
Beneish M-Score
(3.52) (2.86) (2.07) (1.64) (2.44) (1.91) (3.12) (4.02) (3.19) (3.57)
P/Operating CF
35.41 49.40 (1,210.87) (246.88) (868.52) 3,059.15 62.06 (19.26) (21.26) 7.07
P/B ratio
9.57 15.35 15.48 8.57 7.62 12.28 2.11 2.45 5.23 2.81
Price to Tangible BV
11.53 17.68 16.43 8.84 7.77 12.53 2.16 2.53 5.43 2.96
EV/Sales
3.37 6.92 13.51 12.24 16.91 18.57 1.65 2.28 5.14 1.47
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(88.43) (39.55) (58.10) (66.69) (70.91) (136.34) 20.29 (3.04) (6.17) (5.34)
EV/FCF
(60.78) (35.56) (48.57) (51.43) (57.76) (69.33) 76.16 (2.84) (5.69) (4.34)
Quick Ratio
2.03 1.72 3.67 7.17 7.03 4.51 3.12 2.37 3.74 3.51
Current Ratio
2.20 1.81 3.77 7.42 7.38 4.85 3.32 2.61 4.18 3.82
Net Debt/EBITDA
4.57 1.39 5.22 8.28 6.63 4.41 3.09 1.13 0.87 1.11
Debt/Assets
2.48% 1.42% 0.12% 16.74% 10.07% 17.68% 15.29% 0.00% 19.40% 27.14%
Debt/Equity
0.05 0.03 0.00 0.24 0.13 0.27 0.26 0.00 0.43 0.79
Asset Turnover
1.22 1.12 0.91 0.60 0.37 0.45 0.56 0.36 0.42 0.47
Operating CF/Net income
0.22 0.38 1.30 1.05 0.69 0.67 (0.34) 0.69 0.76 0.44
Capex/Depreciation
(0.19) (0.94) (2.41) (0.82) (0.82) (2.32) (0.81) (0.37) (0.62) (0.63)
Interest Coverage
(142.73) (156.26) (16.83) (9.75) (59.06) (49.45) 281.30 (5.55) (5.63) (8.67)
ROE
(40.77%) (105.38%) (26.91%) (14.75%) (17.42%) (12.72%) (21.73%) (65.89%) (85.03%) (74.88%)
ROA
(21.32%) (51.52%) (16.37%) (10.45%) (12.95%) (9.09%) (13.52%) (39.41%) (45.72%) (29.63%)
ROIC
(719.42%) 0.00% (209.91%) (19.95%) (35.88%) (15.66%) (31.79%) (202.78%) (167.23%) (218.36%)
Return on Tangible Assets
(50.30%) (100.41%) (19.83%) (11.36%) (14.20%) (14.20%) (24.62%) (104.26%) (73.08%) (52.03%)
Average Days of Receivables
44.28 86.10 81.12 101.99 130.88 115.31 102.07 99.46 89.24 52.86
Research and Development Expense of Revenue
45.52% 59.29% 49.47% 49.48% 63.98% 53.38% 57.80% 83.95% 77.96% 74.31%
Selling, General and Administrative Expense of Revenue
52.05% 57.99% 48.34% 46.02% 50.75% 47.08% 37.64% 75.92% 92.93% 66.88%
Intangible Assets out of Total Assets
0.09 0.06 0.04 0.02 0.01 0.01 0.01 0.02 0.02 0.02
Share Based Compensation of Revenue
11.62% 14.18% 13.02% 10.14% 11.19% 11.07% 10.48% 14.22% 22.05% 13.67%
Graham Net Nets
0.06 0.04 0.05 0.08 0.10 0.04 0.19 0.20 0.05 0.00
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(4.44%) (6.13%) (1.32%) (1.34%) (1.83%) (1.09%) (10.92%) (35.58%) (18.87%) (31.90%)
Free Cash Flow Yield
(1.48%) (2.58%) (1.93%) (1.80%) (1.56%) (1.39%) 0.99% (26.49%) (15.32%) (16.79%)
Revenue per Share
1.20 1.08 1.16 1.21 1.16 1.62 2.12 1.03 0.81 0.81
Operating CF per Share
(0.05) (0.19) (0.27) (0.22) (0.28) (0.22) 0.17 (0.77) (0.67) (0.22)
Capex per Share
(0.02) (0.02) (0.05) (0.07) (0.06) (0.21) (0.13) (0.05) (0.06) (0.05)
Free Cash Flow per Share
(0.07) (0.21) (0.32) (0.29) (0.34) (0.43) 0.05 (0.83) (0.73) (0.27)
Cash per Share
0.47 0.68 1.02 1.61 2.54 1.82 1.75 0.96 1.01 0.90
Shareholders Equity per Share
0.47 0.53 1.08 1.87 2.87 2.55 2.22 1.27 0.91 0.58
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.47 0.53 1.08 1.87 2.87 2.55 2.22 1.27 0.91 0.58
Free Cash Flow
(2.71) (9.74) (16.86) (16.29) (20.21) (28.06) 3.01 (56.30) (53.63) (23.84)
Working Capital
14.86 20.09 50.09 98.82 159.44 128.52 113.83 57.64 75.12 71.50
Capital Expenditures
(0.85) (0.98) (2.77) (3.73) (3.75) (13.79) (8.28) (3.67) (4.22) (4.47)
Net Current Asset Value
10.68 15.96 45.22 70.65 132.88 79.90 57.30 43.52 16.69 (0.45)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.02 0.05 0.05 0.05 0.13 0.06 0.05 0.07 0.06
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
2.11 0.37 0.24 0.73 0.47 0.28 0.45 0.64 0.48 0.54
Cash ROIC
(6.90%) (17.23%) (15.41%) (7.35%) (5.89%) (8.62%) 1.01% (36.98%) (31.58%) (14.08%)
Accounts Receivable Turnover
7.37 5.64 4.80 4.20 3.15 3.62 3.86 2.42 3.53 5.70
Accounts Payable Turnover
2.56 3.68 3.83 5.51 4.92 7.45 12.19 2.79 3.71 4.25
Inventory Turnover
10.74 15.40 15.53 32.57 20.59 20.91 23.85 5.43 7.26 5.16
Average Days of Payables
158.38 90.31 88.21 61.20 78.89 49.22 31.15 169.46 63.60 60.74
Days of Inventory on Hand
30.88 26.39 17.04 8.66 25.60 19.06 19.47 76.51 40.31 71.02
Average Receivables
6.63 8.86 12.63 16.30 21.95 28.93 35.93 28.94 16.81 12.35
Average Payables
3.82 3.89 3.30 2.84 2.80 2.98 3.12 4.60 4.39 2.20
Average Inventory
0.91 0.93 0.81 0.48 0.67 1.06 1.59 2.36 2.24 1.81
Average Assets
40.15 44.64 66.45 114.18 185.36 234.01 248.39 193.48 142.79 148.40
Average Common Equity
20.99 21.82 40.43 80.91 137.81 167.25 154.59 115.71 76.77 58.73

Fold the line items

Columns are period end dates